Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-14T05:41:36.442Z Has data issue: false hasContentIssue false

Crossover reaction between haloperidol and amoxapine for NMS

Published online by Cambridge University Press:  02 January 2018

Koichi Otani
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036, Japan
Kazuo Mihara
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036, Japan
Motohiro Okada
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036, Japan
Sunao Kaneko
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036, Japan
Yutaka Fukushima
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036, Japan
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1991 The Royal College of Psychiatrists 

References

Baca, L. & Martinelli, L. (1990) Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology, 40, 17971798.CrossRefGoogle ScholarPubMed
Cohen, B. M., Harris, P. Q., Altesman, R. I., et al (1982) Amoxapine: neuroleptic as well as antidepressant? American Journal of Psychiatry, 139, 11651167.Google ScholarPubMed
Halman, M. & Goldbloom, D. S. (1990) Fluoxetine and neuroleptic malignant syndrome. Biological Psychiatry, 28, 518521.CrossRefGoogle ScholarPubMed
Otani, K., Horiuchi, M., KoNDO, T., et al (1991) is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry, 158, 850853.CrossRefGoogle ScholarPubMed
Rosebush, P. & Stewart, T. (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146, 717725.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.